Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma, developed and sold by AstraZeneca . Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma, developed and sold by AstraZeneca . Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
Tezepelumab was approved for medical use in the United States in December 2021, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considered it 2021 to be a first-in-class medication.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).